Hanmi Pharm (KRX:128940) reported third-quarter net income attributable to shareholders of the parent company of 31 billion won, down 43.3% from 54.7 billion won a year earlier.

Sales for the quarter ended September was 362.1 billion won, declining 0.7% from 364.61 billion won in the year-ago period.